Evercore ISI analyst Vedvati Shrotre reiterated a Buy rating on Nova (NVMI – Research Report) on March 14 and set a price target of $300.00.

Evercore ISI upgraded SL Green Realty (SLG) to Outperform from In Line with a price target of $73, down from $74. The shares have dropped ...

The new price target of $99 takes into account the potential of CRISPR Therapeutics' in vivo programs, CTX320 and CTX310. Evercore ISI has assigned a probability of success (POS) of 10% and 5% to ...

Evercore ISI upgraded Capital One Financial to Outperform from In Line, bolstered by the conviction that the bank's "idiosyncratic factors provide upside earnings optionality in the face of ...

Investing.com -- Evercore ISI upgraded Capital One Financial Corp (NYSE:COF) to "Outperform" from "In Line," focusing on long-term earnings upside from its pending acquisition of Discover ...

On Wednesday, Evercore ISI began coverage on Summit Therapeutics plc (NASDAQ:SMMT) shares, assigning an Outperform rating and setting a price target of $30.00. The $13.65 billion market cap ...

CRISPR Therapeutics (CRSP) shares jump after Evercore ISI upgraded the stock to Outperform from In Line. Julie Hyman and Josh Schafer examine what the analysts say about the biotech company on ...

Fintel reports that on March 12, 2025, Evercore ISI Group initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Outperform recommendation. As of March 4, 2025, the average one-year ...

On Wednesday, Evercore ISI upgraded Capital One Financial shares, listed on the NYSE under the ticker COF, from In Line to Outperform, setting a price target of $200.00. Trading at $165.40 with a P/E ...

On Wednesday, Evercore ISI began coverage on Summit Therapeutics plc (NASDAQ:SMMT) shares, assigning an Outperform rating and setting a price target of $30.00. The $13.65 billion market cap company, ...